PCL피씨엘
241820 · KOSDAQ · ₩241820 · 피씨엘
- Market cap
- ₩17B
- Enterprise value
- ₩24B
- P/E
- —
- P/B
- 6.2×
- Dividend yield
- 0.0%
- ROE
- −1,733.1%
- Net margin
- −944.5%
Trailing 12 months from filed financial statements, as of Q3 2025. Dividend yield: the 2024 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩6,040Today: ₩6,040 – ₩6,040₩6,040
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD0.0%
- 1Y0.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 2,782,098
- EPS (12 months)
- −₩16,917
- Earnings yield −280.1%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
PCL stock overview
PCL (피씨엘, KRX: 241820) is listed on KOSDAQ, in the Biotech & Pharma sector. PCL is a Korean in-vitro diagnostics company focused on immunodiagnostics built on its proprietary three-dimensional SG Cap multiplex diagnostic technology. Its shares closed at ₩6,040 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩17B.
Key facts
- Market cap
- ₩17B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- PCL is a Korean in-vitro diagnostics company focused on immunodiagnostics built on its proprietary three-dimensional SG Cap multiplex diagnostic technology.
Quick answers about PCL
- What does PCL do?
- PCL is a Korean in-vitro diagnostics company focused on immunodiagnostics built on its proprietary three-dimensional SG Cap multiplex diagnostic technology. It develops and supplies blood-screening diagnostic products, point-of-care (POCT) products, and platform services, and sells test kits and analyzers for infectious diseases, several cancers, COVID-19, influenza, autoimmune conditions, and pet diseases, while also offering AI-based home care systems and, since 2024, chronic-disease medicines.
- What is the market cap of PCL?
- The market capitalisation of PCL was ₩17B at the close on Oct 27, 2026.
- Who are the largest shareholders of PCL?
- According to the latest official filings, the largest reported holders are Kim So-yeon (18.53%, as of Nov 19, 2024); Olix (4.99%, as of Nov 11, 2024).
- When is the next earnings report from PCL?
- Korean companies rarely announce results dates in advance. Based on when PCL filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
PCL is a Korean in-vitro diagnostics company focused on immunodiagnostics built on its proprietary three-dimensional SG Cap multiplex diagnostic technology. It develops and supplies blood-screening diagnostic products, point-of-care (POCT) products, and platform services, and sells test kits and analyzers for infectious diseases, several cancers, COVID-19, influenza, autoimmune conditions, and pet diseases, while also offering AI-based home care systems and, since 2024, chronic-disease medicines.
Written by AI from the company's latest annual report.
- Korean name
- 피씨엘
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김소연
- Founded
- Feb 2008
- Listed
- Feb 2017
- Listed shares
- 2,782,098
- Fiscal year ends
- Month 12
- Website
- www.pclchip.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- DelistingAug 14, 2026
- Other Market Notice (Notice on Market Measures Following Addition of Grounds for Administrative Issue Designation)May 15, 2026
- Market Notice (Market Notice Regarding Filing for Commencement of Corporate Rehabilitation Proceedings)May 12, 2026
- Material Matters Report (Commencement of Rehabilitation Proceedings Application)May 12, 2026
- Other Market Notice (Notice on Market Measures Following Addition of Grounds for Administrative Issue Designation)Mar 31, 2026
Titles in Korean until English translations are added.
Also known as: PCL / 피씨엘 / 241820 / KRX:241820
Source: KRX statistical information